Compare ITRN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRN | AQST |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | Israel | United States |
| Employees | 2800 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 817.2M | 809.3M |
| IPO Year | 2005 | 2018 |
| Metric | ITRN | AQST |
|---|---|---|
| Price | $40.66 | $6.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $50.00 | $10.00 |
| AVG Volume (30 Days) | 97.1K | ★ 2.7M |
| Earning Date | 11-18-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ 8.81 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $348,409,000.00 | $43,397,000.00 |
| Revenue This Year | $9.12 | N/A |
| Revenue Next Year | $10.70 | $52.69 |
| P/E Ratio | $14.46 | ★ N/A |
| Revenue Growth | ★ 5.20 | N/A |
| 52 Week Low | $28.96 | $2.12 |
| 52 Week High | $45.43 | $7.55 |
| Indicator | ITRN | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 65.61 | 56.36 |
| Support Level | $39.24 | $5.90 |
| Resistance Level | $40.79 | $6.55 |
| Average True Range (ATR) | 1.54 | 0.35 |
| MACD | 0.18 | 0.07 |
| Stochastic Oscillator | 96.15 | 85.47 |
Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services and Telematics products. The Telematics services segment consists of regionally-based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others. The company derives maximum revenue from Israel.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.